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Abstract: 
Introduction: Pneumonia is a common pediatric diagnosis that poses a significant risk for future respiratory disease. 
Multiple investigations have found an association between pneumonia in childhood and decreased adult lung function, 
raising the question of whether childhood pneumonia is a risk factor for chronic obstructive pulmonary disease 
(COPD).  
Objectives of the study: The main objective of the study is to analyze the risk of obstructive lung disease in childhood 
pneumonia among local population of Pakistan.  
Methodology of the study: This study was conducted at Sharif Medical and dental college during February 2018 to 
November 2018. This study was done with the permission of ethical committee. For this purpose we select 50 patients 
of pneumonia (age 1 to 15 years) for further analysis. The patients of both gender were selected for this study. 
Childhood pneumonia was defined by subject self-report.  
Result: Significant differences were observed between patients who received extra-fine versus fine-particle COPD in 
the demographics and baseline characteristics. The COPD treatments prescribed to patients before and at step-up 
are shown in S1 Table in the supporting information.  
Conclusion: In conclusion, the COPD exacerbation rate was higher among the patients who had a history of 
pneumonia or a high rate of COPD exacerbation in the preceding period of 1 year.  
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INTRODUCTION: 
Pneumonia is a common pediatric diagnosis that poses 
a significant risk for future respiratory disease. 
Multiple investigations have found an association 
between pneumonia in childhood and decreased adult 
lung function, raising the question of whether 
childhood pneumonia is a risk factor for chronic 
obstructive pulmonary disease (COPD). Prior studies 
are limited by small sample sizes, short-term follow-
up, absence of post-bronchodilator lung function, 
differing definitions of respiratory illness, sampling 
bias, and recall bias [1]. In patients with COPD, low-
dose ICS/LABA combination has been shown to 
reduce exacerbations, improve quality of life and lung 
function, through an underlying complementary anti-
inflammatory cellular action. However there continues 
to be significant concern regarding inappropriate 
prescribing of high-dose ICS in patients with 
obstructive lung diseases, with untoward 
consequences for patients [2]. 
The first laboratory based observational study was 
conducted in Rawalpindi between 2002 and 2003. The 
study demonstrates a low diagnostic yield for isolated 
pathogens 88 out of 510 specimens (17.25%). Most 
commonly identified pathogen was Haemophilus 
influenzae (HI) with a strikingly high relative 
frequency (64 out of 88) among isolates [3]. However, 
this yield is reported in a majority of paediatric 
population (41 out of 64) with 33 being less than five 
years of age. These figures therefore will not be in any 
way reflective of adult CAP status [4]. 
Indeed, regular use of ICS has been linked to several 
systemic effects, including a higher risk of pneumonia, 
where it is thought that ICS exert an anti-inflammatory 
and immunosuppressive effect that could affect the 
pathogenesis of pneumonia [5]. Most randomized 
controlled trials (RCTs), observational studies and 
meta-analysis, in patients with COPD suggest an 
increased risk of pneumonia with a dose-response 
relationship between ICS and pneumonia, although 
there is some evidence suggesting to the contrary [6].  
Despite the fact that free vaccination is available in 
Pakistan, pneumonia is killing around 92,000 children 
annually under-five years of age, health experts said 
Tuesday during a press briefing to mark upcoming 
World Pneumonia Day on November 12. According to 
the World Health Organisation (WHO) estimates, 
pneumonia accounts for 16 percent of the total child 
deaths making it the leading killer of children less than 
5 years of age globally. Pneumonia is a form acute 
respiratory infection that affects lungs [7].  
Objectives of the study 
The main objective of the study is to analyze the risk 
of obstructive lung disease in childhood pneumonia 
among local population of Pakistan 
 
METHODOLOGY OF THE STUDY 
This study was conducted at Sharif Medical and dental 
college during February 2018 to November 2018. This 
study was done with the permission of ethical 
committee. For this purpose we select 50 patients of 
pneumonia (age 1 to 15 years) for further analysis. The 
patients of both gender were selected for this study. 
Childhood pneumonia was defined by subject self-
report. The questionnaire asked: “Have you ever had 
pneumonia or bronchopneumonia?” and their age at 
the first episode. Subjects were classified as childhood 
pneumonia if they reported an age of first pneumonia 
at < 16 years or “As a child; age not known.”  Patients 
with any other chronic respiratory disease, at any time 
were excluded from the study. 
 
Statistical analyses 
Baseline characteristics of unmatched and matched 
patients prescribed either fine- or extra-fine particle 
ICS are described using summary statistics and 
compared using χ2 or Mann-Whitney U tests as 
appropriate. 
 
RESULT: 
Significant differences were observed between 
patients who received extra-fine versus fine-particle 
COPD in the demographics and baseline 
characteristics, as shown in Table 1. The COPD 
treatments prescribed to patients before and at step-up 
are shown in S1 Table in the supporting information.  
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Table 01: Baseline and clinical characteristics of pneumonia patients with obstructive lung diseases 
  Childhood Pneumonia No Childhood Pneumonia pValueb 
DEMOGRAPHIC 
 Male gender (%) 437 (51.2 %) 4990 (53.6 %) 0.18 
 Mean age, years (SD) 61.7 (8.9) 59.4 (9.0) <0.001c 
 Non-Hispanic white (%) 693 (81.1 %) 6073 (65.3 %) <0.001 
SMOKE EXPOSURE 
 In-utero smoke exposure (%)a 206 (33.0 %) 2082 (30.2 %) 0.18 
 Lived with smoker in childhood (%)a 732 (85.7 %) 7618 (81.9 %) 0.006 
 Mean age started smoking, years (SD) 16.5 (4.4) 16.9 (4.7) 0.06 
 Pack-years of smoking (SD) 49.8 (28.4) 43.7 (24.6) <0.001 
 Current smoking (%) 379 (44.4 %) 5011 (53.9 %) <0.001 
PNEUMONIA HISTORY 
 Ever had pneumonia (%) 854 (100.0 %) 2979 (33.9 %) <0.001 
 Diagnosed with pneumonia by 
healthcare provider (%)a 
821 (96.1 %) 2920 (31.4 %) <0.001 
 Pneumonia childhood age unknown (%) 378 (44.3 %) 0 (0.0 %) <0.001 
 Age first pneumonia in years, mean 
(SD)a 
7.7 (4.5) 42.5 (15.6) <0.001 
 Lifetime pneumonia episodes (SD)a 3.9 (4.9) 
   
Patients stepping-up their ICS therapy to extra-fine particle ICS were significantly less likely to be coded for 
pneumonia compared to those stepping-up to fine-particle ICS, having adjusted for confounders (table 2). 
Table 2: Pneumonia diagnosis by treatment group. 
  Childhood 
Pneumonia 
No Childhood 
Pneumonia 
Impact of Childhood 
Pneumoniaa 
  
  
OR (95 % CI) pValueb 
COPD, GOLD 2-4 405 (59.0 %) 3267 (44.4 %) 1.40 (1.17, 1.66) <0.001 
COPD, GOLD 2-
4 + adjusted for childhood 
asthma 
        1.30 (1.09, 1.55) 0.003 
 
DISCUSSION: 
The role of childhood pneumonia in COPD 
development has been investigated for over sixty 
years. Oswald surveyed 1000 adults with chronic 
bronchitis in London from 1951-53, finding 14.3 % 
reported childhood pneumonia compared to 6 % of 
controls. The pathophysiological mechanisms that 
contribute to an increased susceptibility to pneumonia 
in patients treated with ICS are unclear [8]. In murine 
models, ICS have been shown to significantly increase 
alveolar macrophage efferocytosis (uptake of 
apoptotic cells by alveolar macrophages), thereby 
reducing their ability to combat microbes, 
including Streptococcus pneumoniae, the most 
common cause of community acquired pneumonia in 
patients with COPD [9]. A recent study in a cohort of 
children with persistent asthma taking daily ICS 
showed nearly four times greater oropharyngeal 
colonization with Streptococcus 
pneumoniae compared to children not receiving ICS, 
which may increase the risk of having pneumococcal 
respiratory infections. Several studies have 
demonstrated an intra-class difference between both 
mono-component ICS and fixed combinations of 
ICS/LABA with regard to the risk of pneumonia and 
pneumonia related events in COPD patients [10].  
 
CONCLUSION: 
In conclusion, the COPD exacerbation rate was higher 
among the patients who had a history of pneumonia or 
a high rate of COPD exacerbation in the preceding 
period of 1 year.  
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